Cover Kidney News
Volume/Issue:
Volume 13: Issue 2
Page:
14
Publication Date:
01 Feb 2021
Online Publication Date:
05 Feb 2021
  • 1.

    Wesson DE, et al. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet 2019; 393:1417−1427. doi: 10.1016/S0140-6736(18)32562-5

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Tricida, Inc. Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects with Metabolic Acidosis (VALOR-CKD). ClinicalTrials.gov: NCT03710291. https://clinicaltrials.gov/ct2/show/NCT03710291

    • Search Google Scholar
    • Export Citation
  • 3.

    International Society of Nephrology. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:1−150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf

    • Search Google Scholar
    • Export Citation
Editorial Type:
Special Section

Does Veverimer Hold the Future for Metabolic Acidosis?

Katherine KwonKatherine Kwon, MD, FASN, is a partner with Lake Michigan Nephrology in St. Joseph, MI.

Search for other papers by Katherine Kwon in
Current site
Google Scholar
PubMedClose
Volume/Issue:
Volume 13: Issue 2
Publication Date:
01 Feb 2021
Page:
14
Restricted access
Save